匡小虎,张抒扬

• 1:中国医学科学院北京协和医学院北京协和医院心内科

摘要(Abstract)：

<正>随着人们平均寿命的延长,心力衰竭(heart failure,HF)的患病率日渐增长,其中约5%的患者处于终末期,预后很差。虽然心脏移植仍作为终末期心衰患者的最佳选择,但供

关键词(KeyWords)：

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 匡小虎,张抒扬

参考文献(References)：

• [1]James NK,Susan EW,Roberto ML.Left ventricular assistdevices and other devices for end-stage heart failure:utility ofechocardiography.Curr Cardiol Rep,2010,12:257-264.
• [2]Radovancevic B,Vrtovec B,de Kort E,et al.End-organfunction in patients on long-term circulatory support withcontinuous-or pulsatile-?ow assist devices.J Heart LungTransplant,2007,26:815-818.
• [3]Cheng JM,den Uil CA,Hoeks SE,et al.Percutaneous leftventricular assist devices vs.intra-aortic balloon pump counter-pulsation for treatment of cardiogenic shock:a meta-analysis ofcontrolled trials.Eur Heart J,2009,30:2102-2108.
• [4]Tillmann C,Santhosh JW,John ML.Use of mechanical assistduring high-risk PCI and STEMI with cardiogenic shock.CatheterCardiovasc Interv,2010,75:S1-S6.
• [5]Rose EA,Gelijns AC,Moskowitz AJ,et al.Long-termmechanical left ventricular assistance for end-stage heart failure.N Engl J Med,2001,345:1435-1443.
• [6]Stevenson LW,Miller LW,Desvigne-Nickens P,et al.Leftventricular assist device as destination for patients undergoingintravenous inotropic therapy:a subset analysis from REMATCH(randomized evaluation of mechanical assistance in treatment ofchronic heart failure).Circulation,2004,110:975-981.
• [7]Boehmer JP,Popjes E.Cardiac failure:mechanical supportstrategies.Crit Care Med,2006,34 9 Suppl:S268-S277.
• [8]Feldman CM,Khan SN,Slaughter MS,et al.Improvement inearly oxygen uptake kinetics with left ventricular assist devicesupport.ASAIO J,2008,54:406-411.
• [9]Patlolla V,Patten RD,Denofrio D,et al.The effect ofventricular assist devices on post-transplant mortality:an analysisof the United Network for Organ Sharing Thoracic Registry.J AmColl Cardiol,2009,53:264-271.
• [10]Jugdutt BI.Current and novel cardiac support therapies.CurrentHeart Fail Rep,2009,6:19-27.
• [11]Burkhoff D,Cohen H,Brunckhorst C,et al.A randomizedmulticenter clinical study to evaluate the safety and efficacy of theTandemHeart percutaneous ventricular assist device versusconventional therapy with intraaortic balloon pumping fortreatment of cardiogenic shock.Am Heart J,2006,152:469-468.
• [12]Thiele H,Sick P,Boudriot E,et al.Randomized comparison ofintra-aortic balloon support with a percutaneous left ventricularassist device in patients with revascularized acute myocardialinfarction complicated by cardiogenic shock.Eur Heart J,2005,26:1276-1283.
• [13]Vranckx P,Meliga E,De Jaegere PP,et al.The TandemHeart,percutaneous transseptal left ventricular assist device:a safeguardin high-risk percutaneous coronary interventions.The six-yearRotterdam experience.EuroIntervention,2008,4:331-337.
• [14]Kar B,Forrester M,Gemmato C,et al.Use of the TandemHeartpercutaneous ventricular assist device to support patientsundergoing high-risk percutaneous coronary intervention.JInvasive Cardiol,2006,18:93-96.
• [15]Piazza N,Serruys PW,de Jaegere P.Feasibility of complexcoronary intervention in combination with percutaneous aorticvalve implantation in patients with aortic stenosis usingpercutaneous left ventricular assist device(TandemHeart).Catheter Cardiovasc Interv,2009,73:161-166.
• [16]Seyfarth M,Sibbing D,Bauer I,et al.A randomized clinicaltrial to evaluate the safety and efficacy of a percutaneous leftventricular assist device versus intra-aortic balloon pumping fortreatment of cardiogenic shock caused by myocardial infarction.JAm Coll Cardiol,2008,52:1584-1588.
• [17]Cheng JM,den Uil CA,Hoeks SE,et al.Percutaneous leftventricular assist devices vs.intra-aortic balloon pumpcounterpulsation for treatment of cardiogenic shock:a meta-analysis of controlled trials.Eur Heart J,2009,30:2102-2108.
• [18]Sjauw KD,Konorza T,Erbel R,et al.Supported high-riskpercutaneous coronary intervention with the Impella 2.5 devicethe Europella registry.J AmColl Cardiol,2009,54:2430-2434.
• [19]Tuseth V,Salem M,Pettersen R,et al.Percutaneous leftventricular assist in ischemic cardiac arrest.Crit Care Med,2009,37:1365-1372.
• [20]Lam K,Sjauw KD,Henriques JP,et al.Improvedmicrocirculation in patients with an acute ST-elevation myocardialinfarction treated with the Impella LP2.5 percutaneous leftventricular assist device.Clin Res Cardiol,2009,98:311-318.
• [21]Shinn JA.Implantable left ventricular assist devices.CardiovascNurs,2005,20:22-30.
• [22]Letsou GV,Shah N,Gregoric ID,et al.Gastrointestinal bleedingfrom arteriovenous malformations in patients supported by theJarvik 2000 axial-flowleft ventricular assist device.J Heart LungTransplant,2005,24:105-109.
• [23]Geisen U,Heilmann C,Beyersdorf F,et al.Non-surgicalbleeding in patients with ventricular assist devices could beexplained by acquired von Willebrand disease.Eur J CardioThorac Surg,2008,33:679-684.
• [24]Lietz K,Long JW,Kfoury AG,et al.Outcomes of left ventricularassist device implantation as destination therapy in the post-REMATCH era:implications for patient selection.Circulation,2007,116:497-505.
• [25]Matthews JC,Koelling TM,Pagani FD,et al.The rightventricular failure risk score,a preoperative tool for assessing therisk of right ventricular failure in left ventricular assist devicecandidates.J Am Coll Cardiol,2008,51:2163-2172.
• [26]Butler J,GeisbergC,Howser R,et al.Relationship betweenrenal function and left ventricular assist device use.Ann ThoracSurg,2006,81:1745-1751.
• [27]Lietz K,Miller LW.Destination therapy:current results andfuture promise.Semin Thorac Cardiovasc Surg,2008,20:225-233.
• [28]Dickstein K,Vardas PE,Auricchio A,et al.2010 FocusedUpdate of ESC Guidelines on device therapy in heart failure:anupdate of the 2008 ESC Guidelines for the diagnosis andtreatment of acute and chronic heart failure and the 2007 ESCguidelines for cardiac and resynchronization therapy.Developedwith the special contribution of the Heart Failure Association andthe European Heart Rhythm Association.Eur Heart J,2010,31:2677-2687.